Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies

In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth factor (VEGF) pathway have met with mixed results but t...

Descripción completa

Detalles Bibliográficos
Autores principales: Butters, Oliver, Young, Kate, Cunningham, David, Chau, Ian, Starling, Naureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647870/
https://www.ncbi.nlm.nih.gov/pubmed/31380271
http://dx.doi.org/10.3389/fonc.2019.00618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647870/
https://www.ncbi.nlm.nih.gov/pubmed/31380271
http://dx.doi.org/10.3389/fonc.2019.00618

Ejemplares similares